Q1 2024 Generic Launches

Camber Pharmaceuticals is delighted to announce the successful launch of 14 new generic drugs in the first quarter of this year, bringing vital medications to patients faster. This accomplishment, with nearly one new product introduced each week, reflects the exceptional collaboration between R&D, Regulatory, Quality Control, Supply Chain, Customer Service, and other internal teams. You can see the recently launched products below.
- Oxcarbazepine Oral Suspension (Trileptal®)
- Atorvastatin Tablets (Lipitor®)
- Varenicline Tablets (Chantix®)
- Levonorgestrel & Ethinyl Estradiol Tablets (Alesse®)
- Theophylline ER Tablets (Theophylline®)
- Paliperidone ER Tablets (Invega®)
- Icosapent Ethyl Capsules (Vascepa®)
- Allopurinol Tablets (Zyloprim®)
- Quetiapine Fumarate Tablets (Seroquel®)
- Gabapentin Tablets (Gralise®)
- Aripiprazole Oral Solution (Abilify®)
- Pantoprazole Sodium DR Oral Suspension (Protonix®)
- Rufinamide Oral Suspension (Banzel®)
- Fesoterodine Tablets (Toviaz®)
Recent articles
- Camber Launches 13 New Generic Products in Q1 2025, Sets Ambitious Pace for the Year
- Camber Launches Mycophenolate Mofetil Capsules
- Camber Launches Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution
- Camber’s Triple Play – Featured Generics
- Big Game Commercial
- Charting a Bold Path for 2025